ORION -B- (OFK BE) stock market data APIs
€68.7187
-0(-0%)
as of March 12, 2026
Try our APIs with
free plan!
ORION -B- Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for OFK.BE.
Prev. Close
68.7187
Open
68.7139
High
68.7384
Low
68.6595
52 wk Range
47.5402-71
Market Cap
4 882 M
Dividends (Yield)
0.0443
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ORION -B- data using free add-ons & libraries
Get ORION -B- Fundamental Data
ORION -B- Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-12
- EPS/Forecast: 1.75
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ORION -B- News
New
182,827 Orion Corporation A shares converted into B shares
Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 16 JANUARY 2026 at 9:30 EET 182,827 Orion Corporation A shares converted...
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JANUARY 2026 at 16:30 EET Recommendation by the Orion Nomination Commi...
Assessing Whether Orion Oyj (HLSE:ORNBV) Justifies Its Premium P/E After Strong Recent Returns
Event context and recent share performance Orion Oyj (HLSE:ORNBV) has recently attracted investor attention after a period of strong share performance, with the stock showing positive total returns o...
Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug
Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
